Ljubljana/summary
From 2007.igem.org
(One intermediate revision not shown) | |||
Line 3: | Line 3: | ||
<title>Company Name</title> | <title>Company Name</title> | ||
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> | <meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" /> | ||
- | <link href=" | + | <link rel="stylesheet" href="/igem07/index.php?title=User:RGaber/stylesheet/stylenew_zadaj.css&action=raw&ctype=text/css" type="text/css" /> |
</head> | </head> | ||
<body> | <body> | ||
Line 24: | Line 24: | ||
- | <div id="supportingText"> | + | <div align="justify" id="supportingText"> |
Latest revision as of 18:53, 23 November 2007
Achievements
Prospects for future work and real world applications
- The idea of relying on viral functions could be applied also to other HIV-specific processes (such as genome integration, reverse transcription…).
- Our system based on BioBricks has been useful to prove the principle, but for the real application cellular delivery would be much better applied using vectors based on viral delivery.
- In the case of using viral vectors, therapy could be targeted specifically to cells that can be infected by HIV-1 (e.g. similar to T-cell-directed retroviral delivery systems described by David Baltimore at SB2.0).
- Selection of different effectors will (and can) be made based on further experiments – apoptosis can only be used in 100% leak-proof systems, while antiviral and immune response effectors are not as sensitive.
- Similar systems can be prepared for therapy of many other pathogens, particularly viruses (e.g. yellow fever, SARS, foot and mouth disease…) which contain specific proteases and rely on defined cellular receptors.